Dispatch Bio

Most cancer drugs start with a hunt. You look for a molecule that sits on tumor cells and, ideally, on nothing else - a flag you can aim a therapy at. This works beautifully in blood cancers, where CAR T cell therapy has produced some of the most durable cures modern medicine has to offer. It works poorly in solid tumors, which are roughly 90% of all cancer, because solid tumors are stingy about giving you a clean flag. The antigens they display tend to show up on healthy tissue too, so pointing an engineered immune cell at them risks pointing it at the patient.

Dispatch Bio, a Philadelphia biotech that emerged from stealth in July 2025 with $216 million, has a response to this problem that is either obvious or slightly heretical, depending on your mood: if you cannot find a good target, put one there yourself. This is the whole idea. Rather than screening for a natural antigen, Dispatch uses an engineered virus to install a synthetic antigen - which it calls Flare - directly onto tumor cells. The immune system, which was never going to find a target that wasn't there, now has one that unambiguously is. And because the antigen is synthetic, in principle it can be the same across many different tumor types, which is why the company keeps using the word "universal."

"At Dispatch, we are leveraging the ideal tumor target," CEO Sabah Oney has said, "one that is only expressed by the tumor cells." That sentence is doing a lot of work. The ideal tumor target has historically been a thing biotech companies wish existed. Dispatch's bet is that you can just make it.

In one line: DISP-10 doesn't ask CAR T cells to solve the solid-tumor problem. It changes the tumor so the CAR T cells can. As CSO Barbra Sasu puts it, "DISP-10 creates the right biological context for CAR T cells to function in solid tumors."